Why are long-acting beta agonists (LABAs) not used in acute asthma exacerbations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: April 5, 2025 • View editorial policy

From the Guidelines

Long-acting beta agonists (LABAs) are not used in acute asthma attacks because they have a delayed onset of action and are designed for maintenance therapy, not quick relief. During an acute asthma exacerbation, patients need immediate bronchodilation, which is better provided by short-acting beta agonists (SABAs) like albuterol that work within 5 minutes 1. LABAs such as salmeterol and formoterol are designed to provide sustained bronchodilation over 12-24 hours, making them suitable for preventing symptoms but ineffective for quick relief. Some key points to consider when managing acute asthma include:

  • The need for immediate bronchodilation, which is not provided by LABAs
  • The importance of addressing the underlying inflammatory process, which LABAs do not do
  • The potential for LABAs to mask worsening inflammation, potentially delaying appropriate treatment
  • The safety concerns associated with using LABAs without concurrent inhaled corticosteroids, including increased risk of severe asthma exacerbations and asthma-related deaths 2. For acute asthma management, the standard approach involves SABAs, often with systemic corticosteroids and possibly short-acting anticholinergics like ipratropium bromide. Key characteristics of LABAs that make them unsuitable for acute asthma management include:
  • Delayed onset of action, typically taking 15-30 minutes to begin working and reaching peak effect after several hours
  • Designed for maintenance therapy, not quick relief
  • Lack of anti-inflammatory effects, which can lead to masking of worsening inflammation
  • Safety concerns when used without concurrent inhaled corticosteroids.

From the FDA Drug Label

Do not use for relief of acute symptoms. Concomitant short-acting beta2-agonists can be used as needed for acute relief. Do not initiate Formoterol Fumarate Inhalation Solution in acutely deteriorating patients. Do not initiate in acutely deteriorating asthma or COPD. Do not use to treat acute symptoms.

Long-acting beta agonists (LABAs) are not used in acute asthma because they are not intended for relief of acute symptoms. According to the drug labels 3 and 4, LABAs should not be initiated in acutely deteriorating patients and should not be used to treat acute symptoms. Instead, short-acting beta2-agonists can be used as needed for acute relief. This is also supported by the label for salmeterol (INH) 5, which states that LABAs should not be used to treat acute symptoms in asthma or COPD.

From the Research

Reasons for Not Using Long-Acting Beta Agonists in Acute Asthma

  • Long-acting beta2-agonists (LABAs) are not recommended for use in acute asthma due to concerns about their safety and efficacy in this setting 6.
  • The salmeterol multi-centre asthma research trial (SMART) found an increased risk of asthma deaths and life-threatening events in patients treated with salmeterol, particularly among African-Americans and those not using inhaled corticosteroids (ICSs) 6.
  • LABAs should only be added to the asthma treatment plan if other medicines, including ICSs, do not control asthma 6.
  • The use of LABAs as monotherapy for asthma is concerning, and patients should be initiated and maintained on sufficiently high doses of ICSs before considering additional LABAs 6.

Alternative Treatments for Acute Asthma

  • Short-acting beta2-agonists, such as albuterol, are recommended for relieving acute episodes of bronchial smooth muscle spasm 7.
  • Ipratropium bromide/albuterol has been shown to provide more effective acute relief of bronchospasm in moderate-to-severe asthma than albuterol alone 8.
  • Formoterol, a long-acting beta2-agonist with a rapid onset of action, has been approved in Europe as a reliever medication and may be useful in the outpatient management of mild exacerbations of asthma 9.

Guidelines for LABA Use

  • According to major asthma management guidelines, LABAs should be used only when asthma remains symptomatic in patients already receiving regular ICSs 10.
  • LABAs are safe and beneficial in the control of asthma when used in conjunction with ICSs, but their use in acute asthma exacerbations requires further research 10, 9.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.